GaryNSchwartzMD

Oncology • Lebanon, NH

Associate Professor, Medicine, Geisel School of Medicine

Join to view full profile

Are you Dr. Schwartz?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 78 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1 Medical Center Dr
DHMC Depart Hematologyoncology
Lebanon, NH 03756
Phone+1 603-653-6181

Fax+1 603-653-6191
Is this information wrong?

Summary

Dr. Gary Schwartz, MD is an oncologist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire, Vermont, and Massachusetts. He is affiliated with Dartmouth-Hitchcock Medical Center, White River Junction Veterans Affairs Medical Center, and Catholic Medical Center.

Education & Training

Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 1988 - 1991
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1985 - 1988
Stanford University School of MedicineClass of 1985

Certifications & Licensure

MA State Medical License 1988 - 2025
VT State Medical License 2022 - 2024
NH State Medical License 2000 - 2024
NY State Medical License 1986 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer Start of enrollment: 1997 May 01
Completed
Phase 1
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer Start of enrollment: 2004 Jan 01
Completed
Phase 2
Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers Start of enrollment: 2003 Jan 01
Completed
Phase 1
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function Start of enrollment: 2002 Jul 01
Terminated
Phase 2, Phase 3
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy Start of enrollment: 2006 Jan 01
Terminated
Phase 2
Phase I Study of Aprotinin in Advanced Breast Cancer Start of enrollment: 2006 Jul 01
Terminated
Phase 1
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway Start of enrollment: 2012 Dec 01
Terminated
Not Applicable
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Patient Derived Breast Cancer Xenografts Start of enrollment: 2013 Dec 01
Terminated
Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. Start of enrollment: 2014 Jan 01
Completed
Not Applicable
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2014 May 01
Completed
Phase 2
A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

20 citations
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Pha...
Hope S Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D Pegram, Thomas Bachelot, Gail S Wright, Cristina Saura, Santiag...> ;Journal of Clinical Oncology. 2023 Jan 10
4 citations
Phase Ib Study of the Oral Proteasome Inhibitor Ixazomib (MLN9708) and Fulvestrant in Advanced ER+ Breast Cancer Progressing on Fulvestrant.
Gary N. Schwartz, Kevin Shee, Bianca Romo, Jonathan D. Marotti, Alexei F. Kisselev, Lionel D. Lewis, Todd W. Miller> ;The Oncologist. 2021 Jun 1
1 citations
Plasma DNA as a "liquid biopsy" incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast can...
Mary D. Chamberlin, Jason D. Wells, Kevin Shee, Jennifer R. Bean, Jonathan D. Marotti, Wendy A. Wells, Heidi W. Trask, Fred W. Kolling, Ananta Bhatt, Peter A. Kaufman,...> ;Breast Cancer Research and Treatment. 2020 Jun 19
14 citations
Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer.
Wei Yang, Gary N. Schwartz, Jonathan D. Marotti, Vivian Chen, Nicole A. Traphagen, Jiang Gui, Todd W. Miller> ;Oncotarget. 2018 Jan 15
41 citations
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
William J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Rusl...> ;Clinical Cancer Research. 2016 Jan 15
66 citations
Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center
Laura J. Tafe, Ivan P. Gorlov, Francine B. de Abreu, Joel A. Lefferts, Xiaoying Liu, Jason R. Pettus, Jonathan D. Marotti, Kasia J. Bloch, Vincent A. Memoli, Arief A. ...> ;The Oncologist. 2015 Sep 1
42 citations
Stromal Expression of miR-21 Identifies High-Risk Group in Triple-Negative Breast Cancer
Todd A. MacKenzie, Gary N. Schwartz, Heather M. Calderone, Carrie R. Graveel, Mary E. Winn, Galen Hostetter, Wendy A. Wells, Lorenzo F. Sempere> ;The American Journal of Pathology. 2014 Dec 1
14 citations
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer
Jennifer R. Bean, Sarah R. Hosford, Lynn K. Symonds, Philip Owens, Lloye M. Dillon, Wei Yang, Kevin Shee, Gary N. Schwartz, Jonathan D. Marotti, Kristen E. Muller, Kar...> ;Breast Cancer Research and Treatment. 2015 Jan 1
44 citations
Personalized therapy for breast cancer.
F.B. De Abreu, Gary N. Schwartz, Wendy A. Wells, Gregory J. Tsongalis> ;Clinical Genetics. 2014 Jul 1
62 citations
Longitudinal Assessment of Cognitive Changes Associated with Adjuvant Treatment for Breast Cancer: The Impact of APOE and Smoking
Tim A. Ahles, Yuelin Li, Brenna C. McDonald, Gary N. Schwartz, Peter A. Kaufman, Gregory J. Tsongalis, Jason H. Moore, Andrew J. Saykin> ;Psycho-Oncology. 2014 Dec 1
48 citations
Microwave imaging for neoadjuvant chemotherapy monitoring: initial clinical experience
Paul M. Meaney, Peter A. Kaufman, Lori Muffly, Michael Click, Stephen P Poplack, Wendy A. Wells, Gary N. Schwartz, Roberta M. di Florio-Alexander, Tor D. Tosteson, Zho...> ;Breast Cancer Research. 2013 Apr 24
22 citations
A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue
Margit M. McGowan, Burton L. Eisenberg, Lionel D. Lewis, Heather M. Froehlich, Wendy A. Wells, Alan Eastman, Nancy B. Kuemmerle, Kari M. Rosenkrantz, Richard J. Barth,...> ;Breast Cancer Research and Treatment. 2013 Feb 16
47 citations
ΔNp63α Mediated Activation of Bone Morphogenetic Protein Signaling Governs Stem Cell Activity and Plasticity in Normal and Malignant Mammary Epithelial Cells
Amanda L. Balboni, Justine A. Hutchinson, Andrew J. DeCastro, Pratima Cherukuri, Karen T. Liby, Michael B. Sporn, Gary N. Schwartz, Wendy A. Wells, Lorenzo F. Sempere,...> ;Cancer Research. 2013 Jan 15
Incidence of anthracycline-induced cardiotoxicity in patients with breast cancer: A single center's experience.
Nadeem O, Rauwerdink C, Beggs VL, Parr DD, Kono AT, Schwartz GN> ;J. Clin. Oncol.. 2011-05-20
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D> ;Cancer. 2011-04-01
355 citations
Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve
Tim A. Ahles, Andrew J. Saykin, Brenna C. McDonald, Yuelin Li, Charlotte T. Furstenberg, Brett Hanscom, Tamsin J. Mulrooney, Gary N. Schwartz, Peter A. Kaufman> ;Journal of Clinical Oncology. 2010 Oct 10
Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.
Chu Q, Mita A, Forouzesh B, Tolcher AW, Schwartz G, Nieto A, Soto-Matos A, Alfaro V, Lebedinsky C, Rowinsky EK> ;Clin. Cancer Res.. 2010-05-01
76 citations
Evaluation of Breast Tumor Response to Neoadjuvant Chemotherapy with Tomographic Diffuse Optical Spectroscopy: Case Studies of Tumor Region-of-Interest Changes
Shudong Jiang, Brian W. Pogue, Colin M. Carpenter, Steven P. Poplack, Wendy A. Wells, Christine Kogel, Jorge A. Forero, Lori Muffly, Gary N. Schwartz, Keith D. Paulsen...> ;Radiology. 2009 Aug 1
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
Mita MM, Ochoa L, Rowinsky EK, Kuhn J, Schwartz G, Hammond LA, Patnaik A, Yeh I, Izbicka E, Berg K, Tolcher AW> ;Ann. Oncol.. 2006-02-01
The functions of plasminogen activator inhibitor-1: do we have all the pieces of PAI?
Mulligan-Kehoe, M. J.,Schwartz, G. N.,Zacharski, L. R.> ;Thromb Res. 2006
25 citations
Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-...
Jeffrey Peppercorn, James E. Herndon, Alice B. Kornblith, William P. Peters, Tim A. Ahles, James J. Vredenburgh, Gary N. Schwartz, Elizabeth J. Shpall, David D. Hurd, ...> ;Cancer. 2005 Oct 15
A phase I and pharmacokinetic study of BAY59: a novel taxane.
Ramnath N, Hamm J, Schwartz G, Holden S, Eckhardt SG, Vredenburg MR, Bernacki RJ, Lathia C, Kanter P, Creaven PJ> ;Oncology. 2004-01-01
12 citations
Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy
Lakshmi Pendyala, Gary Schwartz, Patrick F. Smith, Joseph Zdanowicz, Michael Murphy, Frederick H. Hausheer> ;Cancer Chemotherapy and Pharmacology. 2003 Apr 8
A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK> ;Clin. Cancer Res.. 2001-07-01
Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients wit...
Ochoa L, Hurwitz HI, Wilding G, Cohen D, Thomas JP, Schwartz G, Monroe P, Petros WP, Ertel VP, Hsieh A, Hoffman C, Drengler R, Magnum S, Rowinsky EK> ;Ann. Oncol.. 2000-10-01
Join now to see all

Press Mentions

Cyclical Estrogen and Anti-Estrogen Therapy Effective for Treatment of Metastatic Breast CancerMay 18th, 2023
Alternating Estrogen and Anti-Estrogen TherapMay 16th, 2023
Breast Cancer Research at Dartmouth Cancer CenterSeptember 30th, 2023

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

Catholic Medical CenterManchester, New Hampshire
Dartmouth-Hitchcock Medical CenterLebanon, New Hampshire
White River Junction Veterans Affairs Medical CenterWhite River Junction, Vermont